We are live on ! Find out more
DRUG

Bright Minds Biosciences
DRUG

9 hedge funds and large institutions have $257K invested in Bright Minds Biosciences in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.81% more ownership

Funds ownership: 3.39% → 4.2% (+0.81%)

0% more funds holding

Funds holding: 9 → 9 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

17% less capital invested

Capital invested by funds: $310K → $257K (-$52.9K)

Holders
9
Holders Change
–
Holders Change %
0%
% of All Funds
0.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
3
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AI
AdvisorShares Investments
Maryland
+$89K
2
SS
Simplicity Solutions
Minnesota
+$30.6K
3
Renaissance Technologies
Renaissance Technologies
New York
+$18.4K
4
UBS Group
UBS Group
Switzerland
+$3.77K
5
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$143

Top Sellers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
-$29K
2
SG
StoneX Group
New York
-$7.54K

DRUG Hedge Fund Activity: Q1 2023 in Review

9 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Bright Minds Biosciences (DRUG) for Q1 2023, worth a combined $257K — down 17% from $310K a quarter earlier.

Fund positioning in DRUG was balanced in Q1 2023: 2 funds opened new positions, 2 closed out, 3 added to existing stakes and 0 trimmed.

The largest buyer was AdvisorShares Investments, adding an estimated $89K. The largest seller was Virtu Financial, exiting entirely with an estimated $29K sold.

  • 9 institutional investors held Bright Minds Biosciences (DRUG) as of Q1 2023, unchanged from Q4 2022.
  • Funds reported $257K of Bright Minds Biosciences stock for Q1 2023, down 17% quarter-over-quarter.
  • 2 funds opened new Bright Minds Biosciences positions in Q1 2023 and 2 closed out, a net change of 0 holders.
  • The largest Bright Minds Biosciences buyer in Q1 2023 was AdvisorShares Investments, an estimated $89K added.
  • The largest Bright Minds Biosciences seller in Q1 2023 was Virtu Financial, an estimated $29K sold.

Based on aggregated 13F filings for Q1 2023.